DiagnaMed Launches CERVAI™ Healthcare Provider Network, Expanding Access to Brain Health AI Platform
DiagnaMed Holdings Corp. has announced the launch of the CERVAI™ Healthcare Provider Network, a partnership program aimed at expanding access to the company’s brain health AI platform for healthcare providers in Canada and the USA. The program is open to hospitals, doctor offices, medical clinics, research and clinical specialists, and aims to provide value-added services, research, and clinical care for patients seeking to take control of their brain health.
At the core of the CERVAI™ platform is the Brain Age™ Estimation and Brain Health Assessment tool, which is a world first. The Brain Age™ Estimation tool utilizes a novel electroencephalogram headset and machine-learning model, along with proprietary software and standardized data recording protocols, to estimate a user’s brain age. The Brain Health Assessment tool generates clinician-observed measures and a brain health score, helping users be proactive in achieving their brain health goals. Future versions of the platform will incorporate OpenAI’s GPT platform to develop personalized treatment plans.
Fabio Chianelli, Chairman and CEO of DiagnaMed, expressed excitement about the launch of the CERVAI™ platform and the opportunity to partner with healthcare providers. He emphasized the importance of providing value-added services and personalized care for patients looking to improve their brain health. DiagnaMed also plans to launch additional network programs for enterprise organizations, athletic teams, and personal at-home use.
Healthcare providers interested in joining the CERVAI™ Healthcare Provider Network can enroll in the partnership program by visiting DiagnaMed’s website. The program aims to expand access to DiagnaMed’s brain health AI platform and empower healthcare providers to offer innovative solutions and improved care for their patients. By leveraging artificial intelligence and advanced technologies, DiagnaMed aims to revolutionize brain health assessment and treatment.
DiagnaMed Holdings Corp. is a generative artificial intelligence healthcare company focused on developing and commercializing the CERVAI™ brain health AI platform. For more information about the company and its initiatives, interested parties can contact Fabio Chianelli, Chairman and CEO of DiagnaMed.
Disclaimer: This article contains forward-looking statements and information, and readers are cautioned that actual results may differ from those predicted. The article does not constitute an offer to sell or the solicitation of an offer to buy securities. The Canadian Securities Exchange and its Regulation Services Provider have not reviewed or accepted responsibility for the adequacy or accuracy of this release.
Contact:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
